ClinicalTrials.gg
CompletedNCT05112445RICHARDUpdated May 6, 2026

Retinal Ischemia Characterization in Diabetes - "RICHARD"

An observational study in Diabetic Retinopathy, sponsored by Association for Innovation and Biomedical Research on Light and Image. Completed at 1 site in Portugal. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Association for Innovation and Biomedical Research on Light and Image · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
60
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Diabetic Retinopathy by Association for Innovation and Biomedical Research on Light and Image — 2 open to participants now, 3 under way, none of them phase 3. Diabetic Retinopathy · Association for Innovation and Biomedical Research on Light and Image.

Enrollment
12th of 16
60 · median 81
Started
2022
with 1 other
Observational
16 of 18
2 open now
Registered
13th of 18
by date

Among the 18 studies in Diabetic Retinopathy by Association for Innovation and Biomedical Research on Light and Image, this one is the 12th largest by enrollment of the 16 observational ones that give a count, is one of 2 that started in 2022, is one of 16 observational ones, and was the 13th registered.

Diabetic Retinopathy

783 studies on the registry are indexed under Diabetic Retinopathy; 145 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

2 of the 18 studies in Diabetic Retinopathy by Association for Innovation and Biomedical Research on Light and Image are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 93 Diabetic Retinopathy studies recruiting now, 61 (66%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 30 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Diabetic Retinopathy by Association for Innovation and Biomedical Research on Light and Image, or all of them as a file.
02

Study summary

Retinal ischemia characterization in diabetes - RICHARD

Read the detailed description

RICHARD is a non-interventional observational cross-sectional and prospective study. Patients will attend their routine clinical appointments, with 2-years of follow-up. Type 2 diabetic individuals with retinopathy ETDRS DRSS grade 43 with IRMA or grade 47-53 will be recruited and examined using non-invasive methodologies.

The study will be performed at AIBILI Clinical Trials Centre (CEC). Demographic and systemic parameters, such as diabetes duration, medical history, medication, body mass index, and family history of medical conditions (particularly when related to cognitive decline) will be registered at baseline.

All subjects will undergo an annual complete non-invasive ophthalmological examination, which includes, best corrected visual acuity, 7-fields CFP to assess ETDRS DRSS level, structural SD-OCT, SD-OCTA, SS-OCTA and ultra-widefield fundus photography (UWF FP). An invasive ophthalmological examination, the Ultra-wide field fundus fluorescein angiography (UWF FFA) will be obtained from both eyes at baseline (V0, M0) only in subjects with ETDRS DRSS grade 43 for final eligibility (43+IRMA).

Ophthalmological examinations performed will be analyzed at AIBILI Coimbra Ophthalmology Reading Centre (CORC) and Centre for New Technologies e Medicine (CNTM).

Color fundus photography (7-fields) will be acquired at V0 (month 0, baseline, cross-sectional study), V2 (month 12) and V3 (month 24), and then graded and classified according to the ETDRS severity scale by CORC, to allow evaluation of retinopathy progression over two years of follow-up. . At baseline visit (V0) both eyes will be evaluated and the study eye will be selected according to ETDRS DRSS grade (43 with IRMA, 47 or 53). Only the study eye will be considered for the primary statistical analysis; other statistical analyses will include both eyes.

03

Conditions studied

  • Diabetic Retinopathy

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

60 individuals with type 2 diabetes and diabetic retinopathy with ETDRS DRSS grade 43 with IRMA, 47 or 53, with or without previous treatment, will be included in this study, over a recruitment period of 12 months.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diabetes type 2 according to 1985 WHO definition.
  • Age over 18 years old.
  • NPDR levels ETDRS DRSS (43 with IRMA, 47 or 53), based on the ETDRS criteria - 7 fields CFP and UWF FFA for 43 with IRMA after confirmation by the Reading Centre (CORC).
  • Refraction with a spherical equivalent less than 5 diopters
  • Able to provide .

Exclusion criteria

Exclusion Criteria:

  • Presence of diabetic macular edema (DME) involving the center of the macula in the study eye and needing immediate treatment.
  • Presence of CI-DME defined as central subfield thickness on OCT ≥305 µm if male or ≥290 µm if female on Zeiss Cirrus OCT [12] with vision loss and needing immediate treatment.
  • Cataract or other eye disease that may interfere with fundus examinations or OCT/OCTA signal strength.
  • Age-related macular degeneration, glaucoma, vitreomacular disease, other retinal vascular disease, or any ocular condition that, in the opinion of the investigator may affect retinopathy status or alter VA during the study.
  • Any eye surgery, including laser, and anti-VEGF within a period of 6-months.
  • Dilatation of the pupil > 5 mm.
  • > 12% in the last measurement prior to the study visit (V0). Study Eye: Only one eye per subject will be considered for the primary statistical analysis (Study Eye). If both eyes meet the inclusion criteria the study eye will be the one that has a higher level of DR (ETDRS classification). If both eyes have the same ETDRS DRSS grading, the eye with higher BCVA will be chosen. If both eyes have the same BCVA, the right eye will be chosen.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
60 participants (actual)
Target follow-up
24 Months
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. OCTA metrics and predict progression to PDR and/ or CI- DME

    Identify which baseline OCTA metrics and predict progression to PDR and/ or CI- DME best correlate with visual function.

    Time frame: Change from baseline to Month 12

  2. OCTA metrics and predict progression to PDR and/ or CI- DME

    Identify which baseline OCTA metrics and predict progression to PDR and/ or CI- DME best correlate with visual function.

    Time frame: Change from baseline to Month 24

07

Study locations

1 site
  • AIBILI-CEC (AIBILI- Clinical Trials Centre)
    Coimbra, 3000-548, Portugal
08

References and documents

Publications

  • Marques IP, Reste-Ferreira D, Santos T, Mendes L, Martinho AC, Yamaguchi TCN, Santos AR, Pearce E, Cunha-Vaz J. Progression of Capillary Hypoperfusion in Advanced Stages of Nonproliferative Diabetic Retinopathy: 6-month Analysis of RICHARD Study. Ophthalmol Sci. 2024 Oct 16;5(2):100632. doi: 10.1016/j.xops.2024.100632. eCollection 2025 Mar-Apr. PubMed 39639890 ↗
  • Santos AR, Lopes M, Santos T, Reste-Ferreira D, Marques IP, Yamaguchi TCN, Miranda T, Mendes L, Martinho ACV, Pearce L, Cunha-Vaz J. Intraretinal Microvascular Abnormalities in Eyes with Advanced Stages of Nonproliferative Diabetic Retinopathy: Comparison Between UWF-FFA, CFP, and OCTA-The RICHARD Study. Ophthalmol Ther. 2024 Dec;13(12):3161-3173. doi: 10.1007/s40123-024-01054-2. Epub 2024 Oct 26. PubMed 39460896 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Apr 2025, 37 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2021
First posted
Nov 8, 2021
StartActual
Mar 30, 2022
Primary completionActual
Apr 30, 2025
CompletionActual
Apr 30, 2025
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05112445
Lead sponsor
Association for Innovation and Biomedical Research on Light and Image
Responsible party
Sponsor
First posted
Nov 8, 2021
Start date
Mar 30, 2022
Primary completion
Apr 30, 2025
Completion
Apr 30, 2025
Last update
May 6, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion